Retatrutide vs Tirzepatide: What the Trials Show

Side Effect Profile

Both share similar gastrointestinal profiles due to GLP-1 receptor activation:

Glucagon-specific effects (retatrutide only):

• Increased resting heart rate — measured, dose-dependent, covered in detail below
• Enhanced thermogenesis (may cause mild sweating)

For detailed side effect profiles, see Retatrutide Side Effects and Tirzepatide Side Effects.

Heart Rate: The Clearest Measured Difference

This is where the receptor difference stops being academic. Glucagon receptor agonism is positively chronotropic — glucagon administration raises heart rate acutely in humans. Retatrutide activates that receptor; tirzepatide does not.

The trials measured it:

Some analyses attribute an increment of roughly 2-5 bpm specifically to glucagon-receptor activation — the component retatrutide has and tirzepatide lacks. GLP-1 receptor agonists as a class raise resting heart rate by about 2-4 bpm through an autonomic mechanism at the sinoatrial node, so the baseline effect is shared; the glucagon arm is additive on top of it.

Two things worth noting about the retatrutide figure. It is dose-dependent, so it is smaller at lower doses than at the 8-12mg arms where it was most pronounced. And it peaked at around 24 weeks and then declined, rather than rising indefinitely.

Why this may matter more for some people than others

Resting heart rate is not the whole picture — heart rate variability, the beat-to-beat variation that reflects autonomic balance, matters too, and some groups start from a lower baseline.

Perimenopause is the clearest documented example. Oestrogen supports parasympathetic tone, and as it fluctuates and declines through the perimenopausal transition, HRV commonly falls or becomes erratic in women roughly 40-50. Palpitations are correspondingly common: published figures put them at up to 42% of perimenopausal and 54% of postmenopausal women. The heart carries oestrogen receptors involved in regulating electrical signalling, which is the proposed mechanism.

So the reasoning some clinicians apply is straightforward: a compound that adds several bpm on top of an already-destabilised autonomic baseline may be less comfortably tolerated than one that adds fewer.

Here is where the evidence stops. There are no dedicated studies of retatrutide in perimenopausal or menopausal women, and no menopause-specific subgroup analysis has been published. Phase 3 trials are expected to carry more granular sex-specific data; that data is not available yet.

That makes the above a mechanistic inference, not a trial finding — two separately well-documented facts that plausibly interact, with the interaction itself untested. Anyone reporting it as established is overstating what has been measured. Resting heart rate and blood pressure are standard things to discuss with a physician before starting any GLP-1 compound, and more so for anyone with a pre-existing cardiac or autonomic condition.

Cost Comparison

Tirzepatide pricing: Widely stocked across the research vendors we track, in vial sizes from 10mg to 120mg.

Retatrutide pricing: Also widely stocked, from 5mg through 60mg vials, with multi-vial kits at the largest sizes.

For current pricing across vendors, check our Cost Comparison and Live Prices pages.

Insurance coverage: Neither compound is covered for weight loss through traditional insurance, as both are research peptides.

How the Two Are Commonly Compared

The Bottom Line

Retatrutide adds glucagon receptor targeting to the dual agonism tirzepatide uses. In its Phase 2 trial it reported a higher weight-loss figure than tirzepatide reported in its own trials — but those are separate studies, so that is a cross-trial signal rather than a measured margin between the two.

What tirzepatide has is the deeper evidence base: more trial data, a longer published safety record, and a smaller measured effect on resting heart rate.

What is still unknown: retatrutide's Phase 3 trials are ongoing. They are expected to carry larger populations and more granular subgroup data, including sex-specific analysis that does not exist today.

Ready to compare vendors? See our retatrutide vendor rankings for current pricing and COA verification.

Related Reading

Retatrutide Deep Dives:

• Retatrutide Benefits — Complete analysis of the triple agonist mechanism
• Retatrutide Side Effects — Full safety profile and risk management
• Retatrutide Dosing — Titration schedules and optimal dosing

Tirzepatide Resources:

• Tirzepatide Benefits — 8 research-backed effects beyond weight loss
• Tirzepatide Results Timeline — Week-by-week expectations on protocol
• Tirzepatide Bloodwork Guide — 7 labs to track with optimal ranges
• Tirzepatide Side Effects — Safety considerations and side effect management
• Tirzepatide vs Semaglutide — How tirzepatide compares to the original GLP-1 agonist

Related Comparisons:

• Best Places to Buy Retatrutide — ranked vendors with pricing
• Best Weight Loss Peptides 2026 — Complete ranking including both compounds
• Best Metabolic Peptides — Beyond weight loss: comprehensive metabolic benefits
• Retatrutide + Cagrilintide Stack — Layering amylin onto the triple-agonist backbone
• Cagri+Tirz vs Cagri+Sema — Picking the incretin backbone for the amylin layer

References

1. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID: 37366315

2. Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity. N Engl J Med. 2022;387(3):205-216. PMID: 35658024

This article is for educational and research purposes only. It is not medical advice.